Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cancer Vaccines
Study results from Y.X. Xu and colleagues in the area of cancer vaccines published
February 10th, 2009
According to a study from the United States, "HLA-A2 tetramer flow cytometry, IFN gamma real time RT-PCR and IFN gamma ELISPOT assays are commonly used as surrogate immunological endpoints for cancer immunotherapy. While these are often used as research assays to assess patient's immunologic response, assay validation is necessary to ensure reliable and reproducible results and enable more accurate data interpretation." "Here we describe a rigorous validation approach for each of these assays prior to their use for clinical sample analysis. Standard operating procedures for each assay were established. HLA-A2 (A*0201) tetramer assay specific for gp100(209(210M)) and...
Source: Cancer Weekly (2009-02-10)
|
